- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03589859
Computerized Vestibular Rehabilitation
October 31, 2024 updated by: VA Office of Research and Development
Computerized Game-based Vestibular Rehabilitation: Assessment of Feasibility and Motor Learning
Disorders of vestibular function and balance are an important component of many conditions that commonly affect veterans, such as inner ear diseases, diabetes, and traumatic brain injury.
Veterans with vestibular impairment have reduced quality of life, limitations on work and physical activities, and an increased risk of falls.
The goal of this research is to develop a more engaging and effective interactive tool for vestibular rehabilitation to improve the lives of affected veterans.
The first steps in this process will be to test the ability of the application to facilitate vestibular learning and to test its feasibility in vestibular patients.
The hypothesis is that computer-game-based adaptation will induce robust VOR motor learning and will provide an engaging platform for vestibular rehabilitation.
Ultimately, our application has the potential to provide more flexible vestibular exercises that will allow therapy to be customized for each patient.
It will also have the ability to track a patient's progress over time and to advance exercises as function improves.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
24
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Louis Stokes VA Medical Center, Cleveland, OH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Normal volunteers and patients with vestibular hypofunction
Description
Inclusion Criteria:
- GROUP 1: Healthy volunteers: Static visual acuity of at least 20/30 at testing distance
- GROUP 2: Vestibular patients: Unilateral or bilateral vestibular hypofunction, No central vestibular disorder, Static Visual Acuity of at least 20/30 at testing distance
Exclusion Criteria:
- GROUP 1: Peripheral or central vestibular disorder
- GROUP 2: Central vestibular disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Normal Volunteers
Testing motor learning
|
Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
|
|
Vestibular hypofunction
Testing feasibility of rehabilitation game
|
Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vestibulo-ocular Reflex Gain Ratio
Time Frame: VOR measurements to determine gain were performed immediately before and after each approximately 30 minute training session. Pre- and post-training gains were then combined in the VOR gain ratio to determine the training effect.
|
The vestibulo-ocular reflex gain is the relationship between a rotation of the head and the evoked eye movement.
The outcome measure is the ratio of the VOR gain after training to that before training.
VOR gain is determined by a scaled fit of eye speed to evoking head speed (normal gain is 1).
Note that this experiment was not a treatment of impairment but a test of the ability of the vestibular game to elicit motor learning (away from normal) in individuals with intact motor learning.
In that context, an increase in the gain to a value greater than unity (faster eye movement relative to the head movement) is "better" with respect to the training goal, but it is not "better" with respect to real-world visual function, for which a gain of one is the goal.
There is no threshold value for this type of motor learning experiment.
Instead, the question is whether the gain is increased after training, and if so, by what percentage relative to the training goal.
|
VOR measurements to determine gain were performed immediately before and after each approximately 30 minute training session. Pre- and post-training gains were then combined in the VOR gain ratio to determine the training effect.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nausea Scale
Time Frame: Immediately after each 10-minute game block, median value calculated for each participant
|
Participants with vestibular hypofunction rated their nausea after each game block on a scale of 1 to 10.
For each visit, there were up to 3 game-blocks, each of 10-minutes duration.
The number of blocks was determined by the participant.
A higher score is a worse outcome (more nausea).
The average nausea scale rating was determined for each participant.
The final result is the median of these averaged scores.
|
Immediately after each 10-minute game block, median value calculated for each participant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mark F. Walker, MD, Louis Stokes VA Medical Center, Cleveland, OH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2018
Primary Completion (Actual)
November 30, 2022
Study Completion (Actual)
November 30, 2022
Study Registration Dates
First Submitted
July 6, 2018
First Submitted That Met QC Criteria
July 6, 2018
First Posted (Actual)
July 18, 2018
Study Record Updates
Last Update Posted (Estimated)
November 26, 2024
Last Update Submitted That Met QC Criteria
October 31, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C2892-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
A limited set of de-identified data supporting published results will be made available on request, pursuant to a Data Use Agreement.
IPD Sharing Time Frame
Pursuant to Data Use Agreement
IPD Sharing Access Criteria
Pursuant to Data Use Agreement
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vestibular Diseases
-
Medipol UniversityIstanbul Medeniyet UniversityCompletedRehabilitation | Vestibular Hypofunction | Vestibulopathy | Vestibular Exercises | Vestibular Assessment | Unilateral Vestibular DeficitTurkey (Türkiye)
-
Université Catholique de LouvainCompletedVestibular Disease | Vestibular DysfunctionUnited States, Belgium, France
-
Istanbul Medipol University HospitalCompletedVestibular Disease | Vestibular RehabilitationTurkey
-
Cairo UniversityRecruitingPeripheral Vestibular DisordersEgypt
-
Université Catholique de LouvainCompletedVestibular Disease | Vestibular Function DisorderBelgium
-
Assistance Publique Hopitaux De MarseilleUnknownVestibular DisordersFrance
-
University of ManitobaCompletedVestibular Neuronitis | Peripheral Vestibular Disorders | Vestibular Syndromes &/or Disorders (Labyrinthine)Canada
-
University of ZurichCompletedVestibular Perception | Damaged Vestibular SystemSwitzerland
-
University Hospital, Strasbourg, FranceRecruiting
-
United States Naval Medical Center, San DiegoThe Geneva FoundationWithdrawnHearing and Vestibular DisordersUnited States
Clinical Trials on VOR Test
-
Icahn School of Medicine at Mount SinaiNew York University; National Institute on Deafness and Other Communication... and other collaboratorsRecruiting
-
Massachusetts Eye and Ear InfirmaryEnrolling by invitationDizziness | Neurofibromatosis 2 | Vestibular Schwannoma | Vestibular Disorder | Inner Ear DiseaseUnited States
-
Hospices Civils de LyonCompleted
-
Virginia Commonwealth UniversityCompleted
-
Selcuk UniversityCompletedNystagmus Vestibular | Positional Vertigo | Reflexes, Vestibo-OcularTurkey
-
Riphah International UniversityCompletedBenign Paroxysmal Positional Vertigo (Disorder)Pakistan
-
Novartis PharmaceuticalsQuintiles, Inc.CompletedSTOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced DiarrheaNeoplasms | DiarrheaUnited States
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedType 1 Diabetes MellitusJapan
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaboratorsCompletedThe Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ARTHIV-1 InfectionUnited States